During Q4 2018 the big money sentiment decreased to 1.13. That’s change of 0.02, from 2018Q3’s 1.15. 18 investors sold all, 53 reduced holdings as Meridian Bioscience, Inc. ratio fall. 46 grew holdings while 34 funds amassed holdings. Funds hold 38.14 million shares thus 2.14% more from 2018Q3’s 37.34 million shares.
30,198 are held by Thrivent Fin For Lutherans. The Connecticut-based Cubist Systematic Strategies Lc has invested 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Parkside Fincl Natl Bank, a Missouri-based fund reported 43 shs. Great West Life Assurance Can has 57,053 shs for 0% of their capital. 239,388 are owned by Marshall Wace Llp. 6.30 million were reported by Blackrock Incorporated. Meeder Asset Mngmt Incorporated owns 523 shs. Piedmont Investment Advsr Inc has invested 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO). 3,719 were reported by Ls Advsr Ltd Liability Com. Mariner Ltd Liability Co holds 34,051 shs or 0.01% of its capital. Matarin Cap Llc accumulated 188,162 shs. California State Teachers Retirement accumulated 0% or 65,035 shs. Guggenheim Capital Ltd Liability Corporation invested in 43,108 shs or 0.01% of the stock. Fuller Thaler Asset Mngmt holds 0% of its capital in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 1,650 shs. Comml Bank Of Montreal Can holds 0% of its capital in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 81,099 shs.

Meridian Bioscience, Inc. had 1 sale and 0 buys since November 12, 2018. This’s net activity of $681,229.

On April, 25 is anticipated Meridian Bioscience, Inc. (NASDAQ:VIVO)’s earnings report, according to Faxor. EPS of $0.21 is 0.00 % from 2018’s $0.21 EPS. If reported the P/E will be 15.13 with $8.92M profit. Wall Street now predicts 5.00 % EPS growth despite Meridian Bioscience, Inc. last quarter’s EPS of $0.20. The stock decreased 2.53% or $0.33 during the last trading session, reaching $12.71.Currently Meridian Bioscience, Inc. is uptrending after 23.48% change in last April 13, 2018. VIVO has also 248,859 shares volume. The stock outperformed the S&P 500 by 19.11%.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide.The company has $540.04 million market cap. The firm operates through Diagnostics and Life Science divisions.The P/E ratio is 21.18. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

For more Meridian Bioscience, Inc. (NASDAQ:VIVO) news posted recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Karolinska Development’s portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents – Nasdaq” posted on April 03, 2019, “LIVEWELL CANADA CLOSES ACQUISITION OF ACENZIA – Nasdaq” on April 02, 2019, “Celyad Reports Business Update and Full Year 2018 Financial and Operating Results – Nasdaq” with a publish date: March 28, 2019, “Immutep to Present IMP761 Preclinical Results in Global Webcast – Nasdaq” and the last “Morgan Stanley likes Blueprint Medicines in premarket analyst action – Seeking Alpha” with publication date: April 03, 2019.